Eliem Therapeutics (ELYM) Competitors $1.26 +0.07 (+5.88%) As of 07/2/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ELYM vs. FATE, KYTX, BDTX, VXRT, LXEO, LYEL, BYSI, NMRA, NKTX, and FTLFShould you be buying Eliem Therapeutics stock or one of its competitors? The main competitors of Eliem Therapeutics include Fate Therapeutics (FATE), Kyverna Therapeutics (KYTX), Black Diamond Therapeutics (BDTX), Vaxart (VXRT), Lexeo Therapeutics (LXEO), Lyell Immunopharma (LYEL), BeyondSpring (BYSI), Neumora Therapeutics (NMRA), Nkarta (NKTX), and FitLife Brands (FTLF). These companies are all part of the "pharmaceutical products" industry. Eliem Therapeutics vs. Its Competitors Fate Therapeutics Kyverna Therapeutics Black Diamond Therapeutics Vaxart Lexeo Therapeutics Lyell Immunopharma BeyondSpring Neumora Therapeutics Nkarta FitLife Brands Fate Therapeutics (NASDAQ:FATE) and Eliem Therapeutics (NASDAQ:ELYM) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends. Which has more volatility and risk, FATE or ELYM? Fate Therapeutics has a beta of 2.18, suggesting that its stock price is 118% more volatile than the S&P 500. Comparatively, Eliem Therapeutics has a beta of -0.39, suggesting that its stock price is 139% less volatile than the S&P 500. Does the media favor FATE or ELYM? In the previous week, Fate Therapeutics had 2 more articles in the media than Eliem Therapeutics. MarketBeat recorded 2 mentions for Fate Therapeutics and 0 mentions for Eliem Therapeutics. Fate Therapeutics' average media sentiment score of 0.03 beat Eliem Therapeutics' score of 0.00 indicating that Fate Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Fate Therapeutics Neutral Eliem Therapeutics Neutral Do institutionals and insiders hold more shares of FATE or ELYM? 97.5% of Fate Therapeutics shares are held by institutional investors. Comparatively, 69.8% of Eliem Therapeutics shares are held by institutional investors. 5.5% of Fate Therapeutics shares are held by company insiders. Comparatively, 4.7% of Eliem Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has higher earnings & valuation, FATE or ELYM? Eliem Therapeutics has lower revenue, but higher earnings than Fate Therapeutics. Eliem Therapeutics is trading at a lower price-to-earnings ratio than Fate Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFate Therapeutics$13.63M9.42-$186.26M-$1.49-0.75Eliem TherapeuticsN/AN/A-$35.12M-$0.53-2.38 Is FATE or ELYM more profitable? Eliem Therapeutics has a net margin of 0.00% compared to Fate Therapeutics' net margin of -1,318.93%. Eliem Therapeutics' return on equity of -47.03% beat Fate Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Fate Therapeutics-1,318.93% -47.17% -34.60% Eliem Therapeutics N/A -47.03%-45.97% Do analysts recommend FATE or ELYM? Fate Therapeutics presently has a consensus target price of $3.83, suggesting a potential upside of 242.26%. Given Fate Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Fate Therapeutics is more favorable than Eliem Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fate Therapeutics 0 Sell rating(s) 7 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.13Eliem Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryFate Therapeutics beats Eliem Therapeutics on 11 of the 15 factors compared between the two stocks. Get Eliem Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELYM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ELYM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELYM vs. The Competition Export to ExcelMetricEliem TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.49M$783.11M$5.50B$9.01BDividend YieldN/A4.84%5.39%4.11%P/E Ratio-2.381.3027.4220.07Price / SalesN/A222.05398.50109.13Price / CashN/A23.4436.1356.90Price / Book0.326.018.015.70Net Income-$35.12M-$27.64M$3.16B$248.47M7 Day Performance-3.08%0.35%2.08%2.92%1 Month Performance6.78%6.82%4.38%5.77%1 Year Performance-81.63%7.77%35.81%21.39% Eliem Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELYMEliem TherapeuticsN/A$1.26+5.9%N/A-82.5%$37.49MN/A-2.389FATEFate Therapeutics4.1026 of 5 stars$1.14-4.2%$3.83+236.3%-65.2%$136.38M$13.63M-0.77550KYTXKyverna Therapeutics2.0855 of 5 stars$3.22+4.9%$18.50+474.5%-64.8%$132.68M$7.03M-0.9596News CoverageBDTXBlack Diamond Therapeutics3.2993 of 5 stars$2.27-2.6%$14.60+543.2%-38.2%$132.49MN/A37.8390Positive NewsAnalyst UpgradeVXRTVaxart2.3692 of 5 stars$0.56-3.4%$3.00+435.3%-35.4%$132.42M$28.70M-2.08120Positive NewsLXEOLexeo Therapeutics2.5162 of 5 stars$3.96+1.3%$16.60+319.2%-68.8%$129.80M$650K-1.2058News CoverageLYELLyell Immunopharma2.7402 of 5 stars$8.99+3.5%$20.00+122.5%-68.8%$128.68M$60K-0.36270BYSIBeyondSpringN/A$2.74-13.6%N/A-3.0%$127.80M$1.75M0.0080High Trading VolumeNMRANeumora Therapeutics2.5974 of 5 stars$0.75-5.1%$9.29+1,144.7%-92.0%$127.08MN/A-0.46108News CoveragePositive NewsGap UpNKTXNkarta2.2773 of 5 stars$1.75-1.4%$14.33+721.4%-66.9%$125.60MN/A-1.16140News CoverageFTLFFitLife Brands4.3892 of 5 stars$12.99-2.5%$20.50+57.8%-19.0%$125.09M$64.47M15.4620 Related Companies and Tools Related Companies Fate Therapeutics Alternatives Kyverna Therapeutics Alternatives Black Diamond Therapeutics Alternatives Vaxart Alternatives Lexeo Therapeutics Alternatives Lyell Immunopharma Alternatives BeyondSpring Alternatives Neumora Therapeutics Alternatives Nkarta Alternatives FitLife Brands Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELYM) was last updated on 7/3/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredA grave, grave error.Famed financial analyst, Porter Stansberry, calls this technology “The Final Frontier” because it holds the ke...Porter & Company | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold prices are breaking records. But while everyone else is fixated on headlines… They're missing somet...Investors Alley | SponsoredThis Crypto Is Set to Explode in JanuaryFree summit: How to profit from the Coinbase-Deribit deal Our hedge fund experts know exactly what this mea...Crypto 101 Media | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eliem Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eliem Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
